Obagi Medical (NASDAQ: WALD) launched Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 on April 30, 2026. The product is a 100% mineral-filter sunscreen formulated with antioxidants, ceramides, and squalane for sensitive, acne-prone, and post-procedure skin.
It is dermatologist-tested, described as lightweight and non-comedogenic, and is priced at $65, available on Obagi.com, Amazon, authorized providers, and select retailers.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – WALD
+16.64%
31 alerts
+16.64%Session close to close
+42.5%Peak Tracked
-2.2%Trough Tracked
$133.39MMarket Cap
1.4xRel. Volume
In the Apr 30 session, WALD gained 16.64%, reflecting a significant positive market reaction.
Argus tracked a peak move of +42.5% during that session.
Argus tracked a trough of -2.2% from its starting point during tracking.
Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
The stock surged +16.6% in the session following this news. A strong positive reaction aligns with o...
Analysis
The stock surged +16.6% in the session following this news. A strong positive reaction aligns with ongoing efforts to expand Obagi’s suncare and skincare portfolio. Prior Obagi product news sometimes preceded negative moves, while the recent earnings release on Mar 13, 2026 coincided with a gain, suggesting investors reacted more favorably to financial de‑risking. If enthusiasm became extended, past volatility and the stock’s position well below its $1.75 200‑day MA and far from the $3.22 52‑week high could frame reassessment risk.
Key Figures
Share price:$0.763Price change 24h:-2.08%Volume today:38,904,131 shares+5 more
8 metrics
Share price$0.763Pre-news trading level for WALD
Price change 24h-2.08%Move ahead of sunscreen launch announcement
Volume today38,904,131 sharesTrading before/around news; 16.28x 20-day average
20-day avg volume2,389,722 sharesBaseline liquidity for WALD
52-week high$3.22Upper end of 52-week trading range
52-week low$0.7504Lower end of 52-week trading range
200-day MA$1.75Longer-term trend reference, price currently below
Announced Q4/FY25 earnings release timing with no conference call planned.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Obagi/Waldencast news, including product launches and collaborations, often saw negative next‑day moves, while the Q4/FY25 earnings release coincided with a positive reaction.
Recent Company History
Over the past months, Waldencast has mixed operational and regulatory milestones. On Mar 13, 2026, Q4 and FY25 results showed $272.1M net revenue, $16.1M adjusted EBITDA, asset sales, and debt reduction, followed by a positive price reaction. Subsequent Obagi product launches and the ALOHA clinical collaboration drew negative reactions. The Apr 28, 2026 notice that the SEC investigation concluded without recommended enforcement also saw shares down. Today’s sunscreen launch continues this stream of Obagi-focused brand developments.
Key Terms
broad spectrum, spf 40, uva/uvb, non-comedogenic, +4 more
Broad spectrum describes a medical product—such as a drug, diagnostic test, or disinfectant—that is effective against a wide variety of disease-causing organisms or conditions rather than a single specific one. For investors, it signals a larger potential market and simpler clinical positioning, like a Swiss Army knife that works for many problems, but it can also mean higher regulatory scrutiny, competitive crowding, or concerns about side effects and long-term effectiveness.
SPF 40 is a sun protection rating printed on sunscreen that measures how much longer skin covered by the product can resist sunburn from UVB rays compared with unprotected skin; think of it as a multiplier for time in the sun. For investors, SPF 40 signals product performance and marketing position—affecting consumer demand, pricing power, regulatory claims and potential liability—so it influences sales, brand competitiveness and risk assessment.
uva/uvbmedical
"provides broad-spectrum UVA/UVB protection while helping to soothe, hydrate..."
UVA and UVB are two bands of invisible ultraviolet light from the sun: UVA penetrates deeper into skin and ages it, while UVB causes sunburn and is linked to skin damage. For investors, they matter because exposure levels drive demand, regulation and liability for products like sunscreens, window coatings, textiles, eyewear and outdoor equipment — think of them as weather conditions that shape which protective products and rules sell or change value.
non-comedogenicmedical
"The lightweight, non-comedogenic formula is ideal for sensitive, acne-prone..."
Non-comedogenic describes skincare or cosmetic products formulated not to clog pores, which helps reduce the likelihood of acne or skin breakouts. For investors, that label affects how widely a product can be marketed, its appeal to customers with sensitive or acne-prone skin, and potential regulatory or liability exposure—similar to a “no-smoke” label on a building that signals lower fire risk and broader tenant appeal.
antioxidantsmedical
"Formulated with 100% mineral active filters, antioxidants, ceramides, and squalane..."
Antioxidants are substances—molecules found in foods, supplements, and medicines—that slow or stop chemical processes that can damage cells, similar to how a rust inhibitor or a small fire extinguisher prevents wear and tear. Investors care because antioxidant claims and evidence can drive consumer demand, affect product labeling and regulatory scrutiny, influence clinical trial outcomes, and therefore shape sales, reputations, and the valuation of companies in food, wellness and pharmaceutical markets.
ceramidesmedical
"supporting the skin barrier with ceramides and squalane."
Ceramides are a family of naturally occurring fats found in the outer layer of skin that act like mortar between bricks, holding skin cells together to keep moisture in and irritants out. Investors care because ceramides are key ingredients in many skincare, dermatology and wound‑care products, so demand, supply costs, formulation advances, clinical data or regulatory changes can affect sales, margins and the valuation of companies that make or sell these products.
squalanemedical
"supporting the skin barrier with ceramides and squalane."
A lightweight, stable oil used mainly in cosmetics and skin-care products to moisturize and smooth skin; think of it as a gentle cooking oil for your skin that helps products spread and absorb without feeling greasy. It matters to investors because demand, sourcing choices (plant-based vs. animal-derived), price and supply chain stability can affect costs, brand reputation and sales for manufacturers and retailers, and regulatory or sustainability concerns can change market access and margins.
photodamagemedical
"delivers antioxidant defense against photodamage and oxidative stress..."
Photodamage is harm to skin and eyes caused by repeated exposure to ultraviolet and high-energy visible light, producing premature aging (wrinkles, sunspots), weakened skin structure, and a higher risk of skin cancer. For investors it matters because it creates ongoing demand for sunscreens, protective clothing, dermatology treatments, diagnostic testing and regulatory oversight—think of it like sun-driven wear-and-tear that sustains markets for prevention, repair and medical care.
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced the launch of its latest innovation, Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40, a clinically proven mineral sunscreen designed to deliver comprehensive UV protection while supporting skin health.
Formulated with 100% mineral active filters, antioxidants, ceramides, and squalane, this advanced sunscreen provides broad-spectrum UVA/UVB protection while helping to soothe, hydrate, and support the skin barrier. The lightweight, non-comedogenic formula is ideal for sensitive, acne-prone, and post-procedure* skin, making it a versatile addition to any daily skincare regimen.
“This launch represents the continued evolution of Obagi’s suncare portfolio,” said Justin Giouzepis, Chief Marketing Officer. “As the category shifts toward mineral-based, skincare-first protection, we developed this innovation to meet evolving consumer and channel needs while leveraging our medical-grade skincare expertise to strengthen our suncare offering as the first line of defense against premature skin aging and discoloration. This sunscreen delivers effective UV protection and reflects our commitment to high-performance, skincare-first SPF solutions that support a comprehensive daily regimen.”
This new addition to the Obagi Sun Shield™ portfolio reflects growing consumer demand for mineral-based sunscreens that deliver both efficacy and skin compatibility. According to internal insights, a majority of U.S. sunscreen users prefer mineral formulas, particularly those that support overall skin health and barrier function.
“Sun protection is the foundation of healthy skin, especially following professional treatments or when managing sensitivity,” said Dr. Suzan Obagi, Chief Medical Director. “With Sun Shield™ Mineral UV Barrier Protect SPF 40, we’ve combined high-performance mineral protection with restorative skincare ingredients to help patients protect and strengthen their skin every day.”
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 provides broad-spectrum SPF 40 mineral UVA/UVB protection while supporting the skin barrier with ceramides and squalane. The formula also delivers antioxidant defense against photodamage and oxidative stress, and is dermatologist-tested to be lightweight, non-irritating, and non-comedogenic. It is suitable for sensitive, acne-prone, and post-procedure* skin.
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 is now available for $65 on Obagi.com, Amazon.com, as well as through authorized Obagi Medical providers and select retail channels.
About Obagi Medical Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024**, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
What is Sun Shield Mineral UV Barrier Protect SPF 40 from Obagi (WALD) and when was it announced?
It is a 100% mineral broad-spectrum sunscreen announced April 30, 2026. According to Obagi, the formula includes antioxidants, ceramides, and squalane and is intended for sensitive, acne-prone, and post-procedure skin.
How much does Obagi's Sun Shield SPF 40 cost and where can investors buy it (WALD)?
The product retails for $65 and is available now on Obagi.com and Amazon. According to Obagi, it is also sold through authorized Obagi Medical providers and select retail channels.
What active ingredients and skin benefits does Obagi's SPF 40 claim to provide?
The sunscreen uses 100% mineral active filters and contains antioxidants, ceramides, and squalane. According to Obagi, it provides broad-spectrum UVA/UVB protection while supporting skin barrier function and hydration.
Is Obagi's new Sun Shield SPF 40 suitable for post-procedure or sensitive skin (WALD)?
Yes. According to Obagi, the formula is dermatologist-tested as lightweight, non-irritating, and non-comedogenic, and is intended for sensitive, acne-prone, and post-procedure skin.
Does Obagi claim clinical testing for Sun Shield Mineral SPF 40 and what does that mean for consumers?
Obagi describes the product as clinically proven and dermatologist-tested for tolerance and performance. According to Obagi, this indicates internal or clinical evaluations supporting its suitability for sensitive and post-procedure skin.
How does Obagi position Sun Shield SPF 40 within its suncare portfolio and market trends (WALD)?
Obagi positions the product as a skincare-first, mineral-based SPF responding to consumer demand for skin-compatible sunscreens. According to Obagi, it aims to strengthen the Sun Shield portfolio as daily defense against photodamage.
